UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): March 8, 2006
| |
|
|
| Biogen Idec Inc. |
| (Exact name of registrant as specified in its charter) |
| |
| |
|
|
|
|
| Delaware |
|
0-19311 |
|
33-0112644 |
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(I.R.S. Employer
Identification No.) |
| |
|
|
|
|
| |
|
|
| 14 Cambridge Center, Cambridge, Massachusetts |
|
02142 |
| (Address of principal executive offices)
|
|
(Zip Code) |
| |
|
|
Registrant’s telephone number, including area code: (617) 679-2000
| |
|
|
| Not Applicable |
| (Former name or former address, if changed since last report) |
| |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the
filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
TABLE OF CONTENTS
Item 8.01 Other Events
On March 8, 2006, the Registrant and Elan Corporation, plc publicly disseminated a press
release announcing that the Peripheral and Central Nervous System Drugs Advisory Committee of the
U.S. Food and Drug Administration voted unanimously to recommend reintroduction of
TYSABRI® (natalizumab) as a treatment for relapsing forms of multiple sclerosis. The
information contained in the press release is incorporated herein by reference and filed as Exhibit
99.1 hereto.
Item 9.01 Financial Statements and Exhibits
| (c) |
|
Exhibits. |
| |
| |
|
99.1 The Registrant’s Press Release dated March 8, 2006. |